STOCK TITAN

IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
IMUNON, Inc. (IMNN) to host conference call to discuss financial results and clinical development programs for 2023. Focus on DNA-mediated immunotherapy and next-generation vaccines.
Positive
  • None.
Negative
  • None.

LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m. ET on Thursday, March 28, 2024 to discuss financial results for the year ended December 31, 2023 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

To participate in the call, interested parties may dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call. A live webcast of the call will also be available here.

The call will be archived for replay until April 11, 2024, and can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International Toll) using replay access code 8601697. An audio replay of the call will also be available here for 90 days.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is entering a first-in-human study of its COVID-19 booster vaccine (IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:

IMUNONLHA Investor Relations
Jeffrey W. ChurchKim Sutton Golodetz
Executive Vice President, CFO212-838-3777
and Corporate SecretaryKgolodetz@lhai.com
609-482-2455 
jchurch@imunon.com  

# # #


FAQ

When will IMUNON, Inc. host the conference call to discuss financial results?

IMUNON, Inc. will host the conference call on Thursday, March 28, 2024, at 10:00 a.m. ET.

What is the focus of IMUNON, Inc.'s clinical development programs?

IMUNON, Inc. focuses on developing DNA-mediated immunotherapy and next-generation vaccines, including IMNN-001 for ovarian cancer and PlaCCine modality for pathogen antigens.

What is IMNN-001 and its current development stage?

IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer.

What is the PlaCCine modality and its current status?

PlaCCine modality is a proprietary DNA plasmid technology for pathogen antigens expression in preclinical studies for next-generation vaccines.

How can interested parties participate in the conference call?

Interested parties can dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

Imunon, Inc.

NASDAQ:IMNN

IMNN Rankings

IMNN Latest News

IMNN Stock Data

12.88M
9.37M
1.15%
4.47%
4.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LAWRENCEVILLE

About IMNN

celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.